Leap Therapeutics, Inc.
47 Thorndike Street
Suite B1-1
Cambridge, MA 02141
(617) 714-0360
August 6, 2019
Via EDGAR
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Donald Field
|
RE: |
Leap Therapeutics, Inc. |
|
|
Registration Statement on Form S-1 |
|
|
Filed on July 31, 2019 |
|
|
File No. 333-232927 |
Dear Mr. Field:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Eastern time, on August 8, 2019, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Morgan, Lewis & Bockius LLP, by calling Julio E. Vega at (617) 951-8901.
|
|
Very truly yours, | |
|
|
| |
|
|
LEAP THERAPEUTICS, INC. | |
|
|
| |
|
|
| |
|
|
/s/ Douglas E. Onsi | |
|
|
Name: |
Douglas E. Onsi |
|
|
Title: |
Chief Financial Officer and General Counsel |
cc: Julio E. Vega, Morgan, Lewis & Bockius LLP